Vera Therapeutics, Inc. announced progress on its clinical development of atacicept, an investigational therapy for IgA Nephropathy (IgAN), with plans to announce results from the Phase 3 ORIGIN trial ...
The NefIgARD open-label extension demonstrated that extending the course or retreating patients with targeted-release formulation (TRF)-budesonide is safe and effective in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results